S. Norley et al., SIVMAC vaccine studies using whole inactivated virus antigen sequentially depleted of viral proteins, J MED PRIM, 27(4), 1998, pp. 184-192
Groups of four rhesus monkeys were immunised at 0, 1, 2, and 13 months with
whole inactivated SICmac32H, SIVmac depleted of the outer envelope glycopr
otein gp130, virus cores depleted of the lipid membrane (and hence transmem
brane glycoproteins), or purified gag protein. These macaques plus controls
were challenged with either the homologous SIVmac251-32H grown in human ce
lls or the same virus passed once through monkey cells. None of those chall
enged with monkey-grown virus were protected, whereas all in the whole and
gp130-depleted virus groups, and one in the core group resisted challenge w
ith human-grown virus. As the only difference between the challenge viruses
was a single in vitro passage in monkey cells it can be concluded that pro
tection was solely due to human cell components. Finally, passive transfer
of high titer IgG from monkeys infected with the homologous challenge virus
failed to protect monkeys from infection despite the presence of circulati
ng neutralising antibodies.